Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of UGT2B10, UGT2B17, FMO3, and OCT2 genetic variation on nicotine and cotinine pharmacokinetics and smoking in African Americans.

Pharmacogenetics and genomics - 1 Apr 2017

Taghavi Taraneh, St Helen Gideon, Benowitz Neal L, Tyndale Rachel F

Abstract excerpt

OBJECTIVES: Nicotine metabolism rates differ considerably among individuals, even after controlling for variation in the major nicotine-metabolizing enzyme, CYP2A6. In this study, the impact of genetic variation in alternative metabolic enzymes and transporters on nicotine and cotinine (COT) pharmacokinetics and smoking was investigated. METHODS: We examined the impact of UGT2B10, UGT2B17, FMO3, NAT1, and OCT2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Intravenous
Share to Cotinine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucuronosyltransferase

Share to Minor Histocompatibility Antigens

Share to Nicotine

Share to Organic Cation Transport Proteins

Share to Organic Cation Transporter 2

Share to Pharmacogenomic Variants

Source

Open in PubMed Open full text

Identifiers

PMID: 28178031
DOI: 10.1097/FPC.0000000000000269
PMCID: PMC5346034

Genes

FMO3
NAT1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of UGT2B10, UGT2B17, FMO3, and OCT2 genetic variation on nicotine and cotinine pharmacokinetics and smoking in African Americans.PMID 28178031Read ↗

UGT2B10 Genotype Influences Serum Cotinine Levels and Is a Primary Determinant of Higher Cotinine in African American Smokers.Semantic proximity Read ↗

UGT1A and UGT2B genetic variation alters nicotine and nitrosamine glucuronidation in european and african american smokers.Semantic proximity Read ↗

The contribution of common UGT2B10 and CYP2A6 alleles to variation in nicotine glucuronidation among European Americans.Semantic proximity Read ↗

The contribution of common genetic variation to nicotine and cotinine glucuronidation in multiple ethnic/racial populations.Semantic proximity Read ↗

Low Cotinine Glucuronidation Results in Higher Serum and Saliva Cotinine in African American Compared to White Smokers.Semantic proximity Read ↗

UGT2B10 genotype influences nicotine glucuronidation, oxidation, and consumption.Semantic proximity Read ↗

Impact of Genetic Variants in the Nicotine Metabolism Pathway on Nicotine Metabolite Levels in Smokers.Semantic proximity Read ↗

Disposition kinetics and metabolism of nicotine and cotinine in African American smokers: impact of CYP2A6 genetic variation and enzymatic activity.Semantic proximity Read ↗

Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms.Semantic proximity Read ↗

Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake.Semantic proximity Read ↗

The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex.Semantic proximity Read ↗

Nicotine N-glucuronidation relative to N-oxidation and C-oxidation and UGT2B10 genotype in five ethnic/racial groups.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.